Atrium Therapeutics Secures $50 Million Private Placement for Cardiac RNA Research

Key Facts

1Atrium Therapeutics entered into a securities purchase agreement with institutional investors for a private placement.

2The private placement is expected to result in aggregate gross proceeds of approximately $50 million before expenses.

Atrium Therapeutics entered into a securities purchase agreement with institutional investors for a private placement, PR Newswire reported. The financing is expected to result in aggregate gross proceeds of approximately $50 million before deducting fees and expenses. The company intends to use the capital to advance its pipeline in precision cardiology and RNA therapeutics development.

The stock, trading under the ticker RNA, closed at $7.93 on October 7, 2026, matching the price per share set in the common stock purchase agreement. During that session, the instrument reached a day high of $8.13 and a low of $7.93. This capital injection provides a liquidity runway for the firm as it moves its clinical programs forward.